In Brief: Pharmanex v. FDA
This article was originally published in The Tan Sheet
Pharmanex v. FDA: Agency files April 29 motion to dismiss the Pharmanex request for a federal court declaratory judgment that Cholestin cholesterol reduction claims are acceptable under the Dietary Supplement Health & Education Act and that FDA should not take regulatory action against the product as a drug. The agency argues that the complaint should be dismissed because the court lacks "subject matter jurisdiction" and because it seeks to preempt a possible enforcement action based on an informal position taken by FDA in a meeting and thus the matter is not "ripe for review." The complaint was filed in Salt Lake City, Utah federal court April 7 ("The Tan Sheet" April 14, p. 1)...
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC